Register Login

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

SymbolARWR
NameARROWHEAD PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address177 E. COLORADO BLVD,SUITE 700, PASADENA, California, 91105, United States
Telephone+1 626 - 304-3400
Fax—
Email—
Websitehttps://www.arrowheadpharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Additional info from NASDAQ:
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

2026-04-24 22:44

Apel Daniel Joseph 🔴 sold 13.1K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $71.92 Transaction Date: Apr 22, 2026 | Filing ID: 000039

Read more
2026-04-24 22:38

Hamilton James C 🔴 sold 10.0K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $75.00 Transaction Date: Apr 23, 2026 | Filing ID: 000007

Read more
2026-04-24 10:39

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Read more
2026-04-23 20:44

📋 James Hamilton (Officer) plans to sell 10K shares of Arrowhead Pharmaceuticals Inc. (at $75.00 each, total $750K) Filed: Apr 23, 2026 | ID: 026884

Read more
2026-04-22 21:16

📋 Daniel Apel (Officer) plans to sell 13K shares of Arrowhead Pharmaceuticals Inc. (at $71.34 each, total $934K) Filed: Apr 22, 2026 | ID: 026634

Read more
2026-04-20 20:01

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Read more
2026-03-28 14:30

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

Read more
2026-03-26 16:43

New Form SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000629 <b>Size:</b> 7 KB

Read more
2026-03-09 23:00

Hamilton James C 🔴 sold 10.0K shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $64.19 Transaction Date: Mar 05, 2026 | Filing ID: 000006

Read more
2026-03-05 21:49

📋 James Hamilton (Officer) plans to sell 10K shares of Arrowhead Pharmaceuticals (at $64.19 each, total $642K) Filed: Mar 05, 2026 | ID: 015264

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07221344 Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Di… Phase1 Alzheimer Disease Recruiting 2025-11-18 2027-06-01 ClinicalTrials.gov
NCT07037771 A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous F… Phase3 Homozygous Familial Hypercholesterolemia Recruiting 2025-06-17 2027-08-20 ClinicalTrials.gov
NCT06347133 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Phase3 Hypertriglyceridemia Active_Not_Recruiting 2024-05-21 2026-09-01 ClinicalTrials.gov
NCT06138743 Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase1 Myotonic Dystrophy 1 Recruiting 2024-03-04 2026-12-01 ClinicalTrials.gov
NCT05217667 Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia… Phase2 Homozygous Familial Hypercholesterolemia Active_Not_Recruiting 2022-04-22 2025-11-01 ClinicalTrials.gov
NCT04202354 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohe… Phase1 Non-alcoholic Steatohepatitis Completed 2020-03-03 2021-09-03 ClinicalTrials.gov
NCT03365947 Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus… Phase1 Hepatitis B Completed 2018-03-27 2020-04-23 ClinicalTrials.gov
NCT02604199 A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) … Phase2 Hepatitis B Terminated 2015-09-01 2017-01-01 ClinicalTrials.gov
NCT02535416 A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers Phase1 Healthy Completed 2015-09-01 2016-08-01 ClinicalTrials.gov
NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project Phase4 Hypertension Completed 2015-06-01 2022-12-16 ClinicalTrials.gov
NCT02363946 A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Anti… Phase1 Alpha-1 Antitrypsin Deficiency Terminated 2015-02-01 2016-11-01 ClinicalTrials.gov
Total clinical trials: 11
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Tirzepatide Other Phase PHASE1 Obesity RECRUITING NCT06700538
Placebo Other Phase PHASE1 Obesity RECRUITING NCT06700538
ARO-INHBE Other Phase PHASE1 Obesity RECRUITING NCT06700538
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Statins Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT03936361
Total products: 44